Beyondspring (NASDAQ:BYSI) Rating Lowered to Hold at ValuEngine

ValuEngine cut shares of Beyondspring (NASDAQ:BYSI) from a buy rating to a hold rating in a research report report published on Wednesday, ValuEngine reports.

A number of other equities analysts have also weighed in on BYSI. HC Wainwright reiterated a buy rating and set a $41.00 target price on shares of Beyondspring in a research note on Wednesday, September 18th. Zacks Investment Research upgraded Beyondspring from a hold rating to a buy rating and set a $21.00 target price on the stock in a research note on Wednesday.

Shares of NASDAQ BYSI opened at $17.00 on Wednesday. The firm has a market cap of $391.73 million, a P/E ratio of -7.02 and a beta of 1.30. Beyondspring has a 1-year low of $13.06 and a 1-year high of $25.79. The business’s 50 day moving average is $18.37 and its 200-day moving average is $17.41.

Beyondspring (NASDAQ:BYSI) last announced its earnings results on Wednesday, September 18th. The company reported ($0.32) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($0.05). On average, research analysts predict that Beyondspring will post -1.54 earnings per share for the current fiscal year.

A number of large investors have recently modified their holdings of BYSI. BlackRock Inc. acquired a new stake in Beyondspring during the second quarter worth approximately $11,904,000. Vanguard Group Inc. acquired a new stake in Beyondspring during the second quarter worth approximately $956,000. Northern Trust Corp acquired a new stake in Beyondspring during the second quarter worth approximately $720,000. Charles Schwab Investment Management Inc. acquired a new stake in Beyondspring during the second quarter worth approximately $528,000. Finally, Bank of New York Mellon Corp acquired a new stake in Beyondspring during the second quarter worth approximately $516,000. 5.27% of the stock is currently owned by institutional investors and hedge funds.

Beyondspring Company Profile

BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.

Read More: How dollar cost averaging works

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.